Delving into the Latest Updates on Immunose FLU(Eurocine Vaccines AB) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Influenza, Human

Originator Organization

Eurocine Vaccines AB

Active Organization-

Inactive Organization

Eurocine Vaccines AB

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase I/II, randomised, multicentre, partially double-blind (group 1, 2, 4 and 5), parallel-group study designed to primarily evaluate the safety, tolerability and immune response in older adults (age 50 to 75 years) following Immunose™ FLU vaccination at 5 sites in Sweden. A total of 300 subjects will be randomised to 1 of 7 treatment groups. The hypothesis is that Immunose™ FLU is safe and tolerable and will increase the influenza-specific mucosal immune response in older adults.

Start Date09 Feb 2018

Sponsor / Collaborator

Eurocine Vaccines AB

100 Clinical Results associated with Immunose FLU(Eurocine Vaccines AB)

Login to view more data

100 Translational Medicine associated with Immunose FLU(Eurocine Vaccines AB)

Login to view more data

100 Patents (Medical) associated with Immunose FLU(Eurocine Vaccines AB)

Login to view more data

100 Deals associated with Immunose FLU(Eurocine Vaccines AB)

Login to view more data